S&P 500   3,861.24 (+0.15%)
DOW   31,042.03 (+0.26%)
QQQ   328.07 (-0.01%)
AAPL   142.75 (-0.12%)
MSFT   231.73 (+0.96%)
FB   279.50 (+0.54%)
GOOGL   1,886.88 (-0.39%)
AMZN   3,303.07 (+0.28%)
TSLA   882.24 (+0.16%)
NVDA   541.37 (-0.87%)
BABA   261.46 (+0.03%)
CGC   35.92 (+9.15%)
GE   11.70 (+6.46%)
MU   80.63 (-0.80%)
AMD   94.08 (-0.05%)
NIO   59.60 (-0.65%)
T   29.24 (+0.45%)
F   11.39 (+0.89%)
ACB   11.08 (+9.06%)
BA   205.61 (+1.11%)
DIS   171.57 (-0.19%)
NFLX   563.53 (+1.21%)
GILD   67.62 (-0.79%)
S&P 500   3,861.24 (+0.15%)
DOW   31,042.03 (+0.26%)
QQQ   328.07 (-0.01%)
AAPL   142.75 (-0.12%)
MSFT   231.73 (+0.96%)
FB   279.50 (+0.54%)
GOOGL   1,886.88 (-0.39%)
AMZN   3,303.07 (+0.28%)
TSLA   882.24 (+0.16%)
NVDA   541.37 (-0.87%)
BABA   261.46 (+0.03%)
CGC   35.92 (+9.15%)
GE   11.70 (+6.46%)
MU   80.63 (-0.80%)
AMD   94.08 (-0.05%)
NIO   59.60 (-0.65%)
T   29.24 (+0.45%)
F   11.39 (+0.89%)
ACB   11.08 (+9.06%)
BA   205.61 (+1.11%)
DIS   171.57 (-0.19%)
NFLX   563.53 (+1.21%)
GILD   67.62 (-0.79%)
S&P 500   3,861.24 (+0.15%)
DOW   31,042.03 (+0.26%)
QQQ   328.07 (-0.01%)
AAPL   142.75 (-0.12%)
MSFT   231.73 (+0.96%)
FB   279.50 (+0.54%)
GOOGL   1,886.88 (-0.39%)
AMZN   3,303.07 (+0.28%)
TSLA   882.24 (+0.16%)
NVDA   541.37 (-0.87%)
BABA   261.46 (+0.03%)
CGC   35.92 (+9.15%)
GE   11.70 (+6.46%)
MU   80.63 (-0.80%)
AMD   94.08 (-0.05%)
NIO   59.60 (-0.65%)
T   29.24 (+0.45%)
F   11.39 (+0.89%)
ACB   11.08 (+9.06%)
BA   205.61 (+1.11%)
DIS   171.57 (-0.19%)
NFLX   563.53 (+1.21%)
GILD   67.62 (-0.79%)
S&P 500   3,861.24 (+0.15%)
DOW   31,042.03 (+0.26%)
QQQ   328.07 (-0.01%)
AAPL   142.75 (-0.12%)
MSFT   231.73 (+0.96%)
FB   279.50 (+0.54%)
GOOGL   1,886.88 (-0.39%)
AMZN   3,303.07 (+0.28%)
TSLA   882.24 (+0.16%)
NVDA   541.37 (-0.87%)
BABA   261.46 (+0.03%)
CGC   35.92 (+9.15%)
GE   11.70 (+6.46%)
MU   80.63 (-0.80%)
AMD   94.08 (-0.05%)
NIO   59.60 (-0.65%)
T   29.24 (+0.45%)
F   11.39 (+0.89%)
ACB   11.08 (+9.06%)
BA   205.61 (+1.11%)
DIS   171.57 (-0.19%)
NFLX   563.53 (+1.21%)
GILD   67.62 (-0.79%)
Log in
NASDAQ:ALNY

Alnylam Pharmaceuticals Stock Forecast, Price & News

$175.98
+0.29 (+0.17 %)
(As of 01/26/2021 09:56 AM ET)
Add
Compare
Today's Range
$173.84
Now: $175.98
$177.68
50-Day Range
$124.04
MA: $144.28
$172.38
52-Week Range
$84.97
Now: $175.98
$176.78
Volume1,152 shs
Average Volume993,290 shs
Market Capitalization$20.45 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.47
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP). In addition, the company is developing givosiran for the treatment of patients with AHP; lumasiran for the treatment of primary hyperoxaluria type 1, or PH1; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; and vutrisiran for the treatment of ATTR amyloidosis. Alnylam Pharmaceuticals, Inc. has strategic alliances primarily with Sanofi Genzyme; The Medicines Company; Ionis Pharmaceuticals, Inc.; and Regeneron Pharmaceuticals, Inc., as well as collaboration with Vir Biotechnology, Inc. to advance RNAi therapeutics for the treatment of coronavirus infection, including COVID-19. It also has a collaboration and license agreement with Dicerna Pharmaceuticals, Inc. to develop and commercialize investigational ribonucleic acid interference therapeutics for the treatment of alpha-1 antitrypsin deficiency-associated liver disease, as well as Vir Biotechnology, Inc. to develop and commercialize RNAi therapeutics. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Alnylam Pharmaceuticals logo

MarketRank

Overall MarketRank

1.57 out of 5 stars

Medical Sector

343rd out of 1,922 stocks

Pharmaceutical Preparations Industry

180th out of 771 stocks

Analyst Opinion: 2.3Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ALNY
CUSIP02043Q10
Phone617-551-8200
Employees1,323
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$219.75 million
Book Value$12.90 per share

Profitability

Net Income$-886,120,000.00
Net Margins-222.19%

Miscellaneous

Market Cap$20.45 billion
Next Earnings Date2/4/2021 (Estimated)
OptionableOptionable
$175.98
+0.29 (+0.17 %)
(As of 01/26/2021 09:56 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ALNY News and Ratings via Email

Sign-up to receive the latest news and ratings for ALNY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Alnylam Pharmaceuticals (NASDAQ:ALNY) Frequently Asked Questions

How has Alnylam Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)?

Alnylam Pharmaceuticals' stock was trading at $101.89 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ALNY shares have increased by 72.4% and is now trading at $175.69.
View which stocks have been most impacted by COVID-19
.

Is Alnylam Pharmaceuticals a buy right now?

18 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 7 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Alnylam Pharmaceuticals stock.
View analyst ratings for Alnylam Pharmaceuticals
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Alnylam Pharmaceuticals?

Wall Street analysts have given Alnylam Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Alnylam Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is John M. Maraganore's approval rating as Alnylam Pharmaceuticals' CEO?

65 employees have rated Alnylam Pharmaceuticals CEO John M. Maraganore on Glassdoor.com. John M. Maraganore has an approval rating of 99% among Alnylam Pharmaceuticals' employees. This puts John M. Maraganore in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

When is Alnylam Pharmaceuticals' next earnings date?

Alnylam Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, February 4th 2021.
View our earnings forecast for Alnylam Pharmaceuticals
.

How were Alnylam Pharmaceuticals' earnings last quarter?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) announced its quarterly earnings data on Tuesday, November, 10th. The biopharmaceutical company reported ($2.18) EPS for the quarter, missing the consensus estimate of ($1.66) by $0.52. The biopharmaceutical company earned $125.85 million during the quarter, compared to the consensus estimate of $119.05 million. Alnylam Pharmaceuticals had a negative trailing twelve-month return on equity of 65.96% and a negative net margin of 222.19%. The company's quarterly revenue was up 79.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($1.50) EPS.
View Alnylam Pharmaceuticals' earnings history
.

What price target have analysts set for ALNY?

18 analysts have issued 1 year target prices for Alnylam Pharmaceuticals' shares. Their forecasts range from $74.00 to $225.00. On average, they expect Alnylam Pharmaceuticals' stock price to reach $159.17 in the next twelve months. This suggests that the stock has a possible downside of 9.4%.
View analysts' price targets for Alnylam Pharmaceuticals
or view Wall Street analyst' top-rated stocks.

Who are some of Alnylam Pharmaceuticals' key competitors?

What other stocks do shareholders of Alnylam Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alnylam Pharmaceuticals investors own include Alibaba Group (BABA), NVIDIA (NVDA), XOMA (XOMA), Ionis Pharmaceuticals (IONS), Gilead Sciences (GILD), NXP Semiconductors (NXPI), Mylan (MYL), AbbVie (ABBV), Micron Technology (MU) and Advanced Micro Devices (AMD).

Who are Alnylam Pharmaceuticals' key executives?

Alnylam Pharmaceuticals' management team includes the following people:
  • Dr. John M. Maraganore, CEO & Exec. Director (Age 57, Pay $1.79M)
  • Dr. Yvonne L. Greenstreet M.B.A., MBChB, MBA, Pres & COO (Age 57, Pay $1.14M)
  • Mr. Jeffrey V. Poulton, Chief Financial Officer (Age 52, Pay $681.75k)
  • Dr. Akshay K. Vaishnaw, Pres of R&D (Age 57, Pay $986.1k)
  • Dr. Alfred W. Boyle Ph.D., Sr. VP of Technical Operations
  • Dr. Kevin Fitzgerald, Sr. VP & Chief Scientific Officer
  • Ms. Christine Regan Lindenboom, Sr. VP of Investor Relations & Corp. Communications
  • Ms. Laurie Bartlett Keating J.D., Exec. VP, Chief Legal Officer & Sec. (Age 66)
  • Ms. Nereyda Garcia, Global Head of Ethics & Compliance
  • Mr. Mark Baglin, VP of Global Marketing

What is Alnylam Pharmaceuticals' stock symbol?

Alnylam Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNY."

Who are Alnylam Pharmaceuticals' major shareholders?

Alnylam Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Candriam Luxembourg S.C.A. (0.14%), Rhenman & Partners Asset Management AB (0.10%), State of Alaska Department of Revenue (0.03%), DNB Asset Management AS (0.01%), Nisa Investment Advisors LLC (0.01%) and IFM Investors Pty Ltd (0.01%). Company insiders that own Alnylam Pharmaceuticals stock include Akshay Vaishnaw, Barry E Greene, John Maraganore, Laurie Keating, Marsha Fanucci, Philip A Sharp, Phillip A Sharp, Steven M Paul and Yvonne Greenstreet.
View institutional ownership trends for Alnylam Pharmaceuticals
.

Which major investors are selling Alnylam Pharmaceuticals stock?

ALNY stock was sold by a variety of institutional investors in the last quarter, including Strs Ohio, Candriam Luxembourg S.C.A., State of Alaska Department of Revenue, and IBM Retirement Fund. Company insiders that have sold Alnylam Pharmaceuticals company stock in the last year include Akshay Vaishnaw, Barry E Greene, John Maraganore, Laurie Keating, Phillip A Sharp, Steven M Paul, and Yvonne Greenstreet.
View insider buying and selling activity for Alnylam Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Alnylam Pharmaceuticals stock?

ALNY stock was acquired by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Exchange Traded Concepts LLC, Nisa Investment Advisors LLC, DNB Asset Management AS, IFM Investors Pty Ltd, Pacer Advisors Inc., and Gateway Investment Advisers LLC.
View insider buying and selling activity for Alnylam Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Alnylam Pharmaceuticals?

Shares of ALNY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Alnylam Pharmaceuticals' stock price today?

One share of ALNY stock can currently be purchased for approximately $175.69.

How big of a company is Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals has a market capitalization of $20.41 billion and generates $219.75 million in revenue each year. The biopharmaceutical company earns $-886,120,000.00 in net income (profit) each year or ($8.11) on an earnings per share basis. Alnylam Pharmaceuticals employs 1,323 workers across the globe.

What is Alnylam Pharmaceuticals' official website?

The official website for Alnylam Pharmaceuticals is www.alnylam.com.

How can I contact Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals' mailing address is 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-551-8200 or via email at [email protected]

This page was last updated on 1/26/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.